Login
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC

orasure.com

What Do They Do?

Sells rapid diagnostic tests and sample-collection devices to healthcare and public-health organizations, consumers, and laboratories and researchers.

How Do They Make Money?

Customers buy diagnostic tests and sample-collection products; they generally pay after shipment, though some pay before delivery. Other income comes from royalties linked to licensee sales and funding for research work, paid as activities are performed.

revenue
SegmentShareRevenue
Products and services
Sold outright

95%
FY2022: 98%
Other
Mix

5.2%
FY2022: 2.4%

Who Are Their Customers?

Healthcare and public-health organizations and consumers buy diagnostic tests; laboratories, researchers and pharmaceutical companies buy sample-collection products. Sales use direct channels, strategic arrangements and independent distributors.

Do Revenues Turn Into Profits?

No. It lost $68.7M in FY2025.

Operating income, FY2025
−63% of revenue
▼ −155% (Loss) vs FY2024 (−$28.3M, −15%)
Net income, FY2025
−60% of revenue
▼ −252% (Loss) vs FY2024 (−$19.5M, −10%)
Free cash flow, FY2025
−46% of revenue
▼ Turned to a loss vs FY2024 ($23.6M, 13%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +14%
vs $27.1M in Q3 FY2025
Net income
▲ +5% (Loss)
vs −$13.7M in Q3 FY2025
Products and services share of revenue vs 93.5% in Q3 FY2025
  • Nov 9, 2026 Company gives fourth-quarter revenue guidance and expects faster growth Q4 revenue guidance is $30.0 million to $32.0 million; the company expects faster full-year revenue growth in 2027.
  • May 6, 2026 Company provides second-quarter revenue guidance The company guides to Q2 2026 total revenue of $27 million to $30 million.

Shrinking. Revenue fell 51% in 4 years, from $233.7M in FY2021 to $115M in FY2025, about 16% a year.

Sickle-cell diagnostics The older report described rapid HIV and hepatitis C tests; the newer report says the BioMedomics acquisition added SickleSCAN, a rapid sickle-cell disease test.

Risk-assessment testing The older report included drug-of-abuse tests processed in a laboratory; the newer report says the risk-assessment product line was discontinued.

Laboratory services The older report said Diversigen offered laboratory and analytical services for genomics and microbiome customers; the newer report says OraSure exited molecular services.

Revenue over time
Products and services Other
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support